First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
Publication date
2022-06
Authors
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.
Keywords
(3–6): oligometastases, MOMENTUM, MR-guided radiotherapy, MR-Linac, SABR, Care Planning, Oncology(nursing), Health Policy, Radiology Nuclear Medicine and imaging, Journal Article
Citation
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium 2022, 'First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac', Technical Innovations and Patient Support in Radiation Oncology, vol. 22, pp. 50-54. https://doi.org/10.1016/j.tipsro.2022.04.005